AuroBlog - Aurous Healthcare Clinical Trials blog

AUGUST 22, 2024

Neurons aren’t the only brain cells producing the proteins associated with Alzheimer’s disease, a new study of mouse models reveals. Amyloid beta proteins occur naturally in our brains, but have long, and now controversially, been associated with Alzheimer’s disease. “Until now, neurons were […]

Protein 245

Protein Clinical Trials Clinical Trials Clinical Research 245

XTalks

MARCH 11, 2025

Vepdegestrant, an investigational oral therapy, utilizes PROteolysis TArgeting Chimera (PROTAC) technology a mechanism that harnesses the bodys natural protein disposal system to selectively target and degrade the estrogen receptor.

Trials 59

Trials Clinical Trials Clinical Trials Protein 59

AuroBlog - Aurous Healthcare Clinical Trials blog

JANUARY 23, 2023

Six minutes of high-intensity exercise is enough to produce a key protein in the brain, one that’s important in brain formation, function, and memory, and which has been implicated in the progress of neurodegenerative disorders such as Alzheimer’s disease.

Protein 243

Protein Clinical Trials Clinical Trials Clinical Research 243

Pharmaceutical Technology

OCTOBER 18, 2022

Last week, Nature magazine published a paper detailing an in-situ study of Parkinson’s disease (PD), showing protein structural changes in cerebrospinal fluid (CSF) between healthy individuals and Parkinson’s patients. In PD clinical research, many biomarkers, such as neurofilament, can be measured within the CSF using a lumbar puncture.

Protein 264

Protein Genetics Gene Clinical Research 264

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 5, 2024

The first twin study of its kind suggests that taking daily protein and prebiotic supplements can improve scores on memory tests in people over the age of 60. What’s good for your aging gut may also be good for your aging brain. The findings are food for thought, especially as the same visual memory and […]

Protein 246

Protein Clinical Trials Clinical Trials Clinical Research 246

XTalks

DECEMBER 26, 2024

Menarini Group has announced positive topline data from the Phase III BROADWAY and TANDEM clinical trials, evaluating obicetrapib and the fixed-dose combination of obicetrapib with ezetimibe. Meanwhile, the TANDEM trial evaluated a fixed-dose combination of obicetrapib with 10 mg ezetimibe in a similar patient population.

Trials 52

Trials Life Science Clinical Trials Clinical Trials 52

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2023

The team, led by researchers from Stanford University, adapted a technique used for analyzing eye fluid. Almost 6,000 proteins detected in the fluid could be traced […]

Protein 245

Protein Scientist Research Development 245

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 30, 2023

Key to this newly discovered process is GRP78, and it’s what’s known as a chaperone protein. One of the challenges in treating cancer is stopping it from metastasizing, and a new study reveals one of the fundamental mechanisms through which this happens. Now we know about this mechanism, perhaps we can stop it.

Scientist 246

Scientist Protein Clinical Trials Clinical Trials 246

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 2, 2024

Alzheimer’s disease is commonly associated with clumps and tangles of proteins building up in brain cells. A study led by researchers from the Stanford University School of Medicine returned to observations of large fat drops […]

Protein 233

Protein Medicine Research Clinical Trials 233

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 21, 2022

In July 2022, Science magazine reported that a key 2006 research paper, published in the prestigious journal Nature, which identified a subtype of brain protein called beta-amyloid as the cause of Alzheimer’s, […].

Protein 236

Protein Research Clinical Trials Clinical Trials 236

XTalks

OCTOBER 24, 2024

Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. In August 2024, Artax Biopharma completed patient recruitment for its Phase IIa trial of AX-158, exploring a new immune-modulating therapy for psoriasis.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

XTalks

OCTOBER 23, 2024

Otsuka Pharmaceutical has announced positive interim results from its Phase III clinical trial for sibeprenlimab. The Phase III VISIONARY trial enrolled 530 adults aged 18 to 65, with varying degrees of kidney function, and most were at risk of progressing to end-stage kidney disease.

Trials 101

Trials Clinical Trials Clinical Trials Antibody 101

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

Bioengineer

JANUARY 22, 2025

The research, led by Dr. Daniel McIsaac, an anesthesiologist and senior scientist at The Ottawa Hospital, compiles data from over 15,000 patients involved in 186 randomized clinical trials internationally. These trials are vital as they not only expand the patient pool but also enhance the generalizability of findings.

Trials 59

Trials Clinical Trials Clinical Trials Research 59

XTalks

DECEMBER 20, 2022

While clinical trials are becoming more complex, oncology trials have generally had a greater level of complexity than trials in many other disease spaces. Despite this, the number of oncology trials worldwide has increased dramatically over the past two decades. Regulatory Considerations.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Regulation 97

pharmaphorum

DECEMBER 16, 2020

AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe. The antibody targets a conserved region of the SARS-CoV-2 spike protein and has been developed through a collaboration between Harbour (HBM) and Utrecht University (UU).

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

DECEMBER 7, 2022

Last week, the quest for an effective Alzheimer’s disease therapy received a notable fillip at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022, with new data on Eisai’s disease-modifying therapy lecanemab. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals.

Development 246

Development Drugs Clinical Trials Clinical Trials 246

XTalks

DECEMBER 12, 2023

The world of neuroscience trials is rapidly evolving, presenting new challenges and opportunities for researchers and clinicians. The worldwide market for neurology clinical trials stood at a valuation of $5.24 There is currently a heightened emphasis on imaging and liquid biomarkers in neuroscience clinical trials.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. By inhibiting this protein, povorcitinib reduces the inflammatory signals that contribute to abscess and nodule formation. for placebo.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

Pharmaceutical Technology

APRIL 28, 2023

Generate Biomedicines has signed a co-development and commercialisation agreement with the University of Texas MD Anderson Cancer Center to expedite the development of new protein therapeutics for oncology using generative AI.

Development 130

Development Clinical Trials Clinical Trials Protein 130

XTalks

JUNE 11, 2024

These statistics underscore the urgent need for innovative treatments and inclusive clinical trials that can address the diverse needs of the lupus population. The complexity of lupus, combined with its significant impact on individuals and communities, makes it a critical area of focus for rheumatology research.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Roots Analysis

MARCH 2, 2022

Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Pipeline Overview of Oral Peptide and Protein-based Therapeutics. Oral Protein / Peptide-based Drugs. Oral Protein / Peptide-based Drugs.

Protein 52

Protein Drugs Drug Delivery Drug Delivery Systems 52

XTalks

SEPTEMBER 17, 2020

In rare disease trials, it’s not always feasible to choose clinically-relevant endpoints to measure the efficacy of a new therapeutic. Verifying the biomarker’s clinical validity for use as a surrogate endpoint in rare disease research is another hurdle which is generally a longer-term goal.

Trials 98

Trials Gene Hormones Clinical Trials 98

Pharmaceutical Technology

JULY 18, 2022

receptor antagonist indicated for the treatment of severe eosinophilic asthma, is currently being investigated in the Phase III MAHALE trial (NCT05006573). The Phase II WILLOW trial (NCT03218917) assessed the efficacy, safety, tolerability and pharmacokinetics of brensocatib and has reported positive results.

Marketing 147

Marketing Trials Development Protein 147

Velocity Clinical Research

AUGUST 8, 2024

Before that, he’d spent 36 years in primary care, treating patients skewed toward the age group most at risk of Alzheimer’s, and it was this experience that, in part, encouraged him to cross over into clinical research. “It The importance of clinical trials That hope is a motivator for many clinical trial participants.

Clinical Trials 105

Clinical Trials Clinical Trials Genetics Clinical Research 105

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

DECEMBER 29, 2023

Reese, executive vice president of Research and Development at Amgen, in the company’s press release. Tarlatamab is an investigational drug currently undergoing clinical trials to assess its efficacy in patients with two distinct types of neuroendocrine cancer: SCLC and neuroendocrine prostate cancer (NEPC).

Clinical Trials 119

Clinical Trials Clinical Trials FDA Approval Trials 119

Pharmaceutical Technology

MAY 31, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Aprea Therapeutics overview Aprea Therapeutics is a biopharmaceutical company that develops cancer therapeutics that reactivate mutant tumor suppressor protein, p53.

Production 100

Production Clinical Trials Clinical Trials Development 100

Pfizer

FEBRUARY 16, 2023

These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Camargo

APRIL 28, 2021

The first tasks in striking this balance are dose selection and dosing interval determination, and this blog post offers an overview on how PK modeling and simulation can be applied to optimize the safety and efficacy of a product for pediatric populations in clinical trials. First Steps Toward Initiating Pediatric Clinical Studies.

Clinical Trials 130

Clinical Trials Clinical Trials In-Vivo Drugs 130

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Why is it Difficult to Develop CNS Therapeutics?

Trials 83

Trials Drug Delivery Drugs Gene 83

pharmaphorum

FEBRUARY 10, 2021

HER-2+ breast cancer is a type of cancer with a high presence of human epidemic growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells. In the PHERGain-II trial, patients will be given preoperative treatment with trastuzumab and pertuzumab, aimed at blocking HER2, without chemotherapy.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Protein 98

Trialfacts

MARCH 7, 2025

This study offers a simple blood test to detect an abnormal protein associated with Alzheimers disease in adults aged 65 to 80. The majority of participants (about 96%) will not have this abnormal protein and will not progress further in the study. Interested? Take our questionnaire and find out if this study is right for you.

Protein 52

Protein Clinical Research Research Nurses 52

Olympian Clinical Research

JUNE 27, 2023

Your diet should feature: Fruits and vegetables Lean proteins like fish and chicken Whole grains, legumes, nuts, and seeds Potassium-rich foods like bananas, avocados, acorn squash, and sweet potatoes Foods to Avoid Some foods are more likely to trigger skin irritation and eczema flare-ups. appeared first on Olympian Clinical Research.

Clinical Research 52

Clinical Research Packaging Packaging Research 52

The Pharma Data

JANUARY 12, 2021

a biopharmaceutical company focused on the development of first-in-class therapeutics for the treatment of cancer, today announced the completion of the Phase 1b clinical trial conducted by the NCI with its lead clinical candidate zotiraciclib (ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

pharmaphorum

SEPTEMBER 12, 2022

Reddy says one of LabCorp’s groundbreaking tests, OmniSeq INSIGHT, is an “all-in-one test that includes comprehensive genomics and immune profiling from a single tissue sample to identify all FDA-approved therapeutics, confirm immunotherapy eligibility for a patient, and identify appropriate nearby clinical trials.”.

Genome 105

Genome Genomics Clinical Trials Clinical Trials 105

pharmaphorum

OCTOBER 21, 2022

The acquisition of DJS Antibodies, a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug disease-causing proteins – such as G protein-coupled receptors (GPCRs) – will extend AbbVie’s present discovery research capabilities, through DJS’ proprietary HEPTAD platform.

Antibody 59

Antibody Protein Research Medicine 59